Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02200562
Title Ipilimumab and Dabrafenib in the 1st Line Tx of Unresectable Stage III/IV Melanoma
Recruitment Terminated
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors University of Utah
Indications
Therapies
Age Groups: adult
Covered Countries USA

Additional content available in CKB BOOST